itacitinib

Itacitinib is an orally administered, selective small molecule inhibitor of Janus kinase 1 (JAK1), developed by Incyte. By selectively inhibiting JAK1, it blocks the phosphorylation of signal transducer and activator of transcription (STAT) proteins and reduces the production of proinflammatory cytokines such as interleukin‑23 (IL‑23) and interleukin‑6 (IL‑6). This mechanism modulates immune responses and inflammation, making itacitinib a candidate for treating diseases characterized by immune dysregulation or excessive inflammation. It has been investigated in clinical trials for conditions including graft-versus-host disease (GVHD), myelofibrosis, rheumatoid arthritis, bronchiolitis obliterans syndrome after lung transplantation, hemophagocytic lymphohistiocytosis (HLH), various solid tumors, B-cell malignancies, melanoma, endometrial cancer, and metastatic cancer[1][2][3][4][5][8].

Brand names

Ikomio

Other names

itacitinib adipate